FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
What Most People Get Wrong About Schizophrenia
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Taking drugs like LSD and ecstasy can increase your risk of schizophrenia, according to new study
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
Everyday Health4d
Phases of Schizophrenia: Prodromal Phase, Active Phase, and Residual Phase
“The journey through these phases varies for each person and may cycle, depending on the response to treatment and external stressors,” says Michael Kane, MD, a psychiatrist and the chief ...
BioPharma Dive3d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
clinicaladvisor.com1d
High MMP9 Predicts Poor Antipsychotic Treatment Response in Schizophrenia
Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.
MedPage Today3d
Magnetic Stimulation Reduced Auditory Hallucinations in Patients With Schizophrenia
For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...
Zacks.com on MSN2d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...
AbbVie shares tumble after schizophrenia drug disappoints
US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms ...
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...
Glial Cells May Influence Depression and Schizophrenia
New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.